SpringWorks Therapeutics Inc. in Stamford, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, recently appointed James (Jim) Cassidy, M.D., Ph.D., as chief medical officer. He brings more than 30 years of experience in oncology as an academic physician-scientist and a drug development leader in both biotechnology and pharmaceutical companies. Cassidy succeeds Jens Renstrup, M.D., MBA, who will be leaving the company.
Cassidy joins SpringWorks from Regeneron Pharmaceuticals, where he was vice president of oncology strategic program direction. Previously he was corporate vice president of translational development at Celgene and before that he was vice president of oncology at Bristol-Myers Squibb and held several roles at Hoffmann La-Roche. Before joining Roche, he had been a leading academic physician-scientist, most recently having served as professor of oncology, head of the Department of Cancer Research and head of the Division of Cancer Sciences and Molecular Pathology at the University of Glasgow in Scotland where he received his medical degree and doctorate.
SpringWorks has a differentiated targeted oncology portfolio of small molecule product candidates and is advancing two potentially registrational clinical trials in rare tumor types as well as eight programs addressing highly prevalent, genetically defined cancers.
